Central sensitization and autonomic symptoms (VIDEO)

Dr. Peter Novak is a neurologist whose research and clinical work has focused on the central nervous system's role in generating the peripheral symptoms of POTS, ME/CFS, and dysautonomia. In this lecture, he makes an argument that reorients the clinical logic most patients have encountered: the tachycardia, the blood pressure instability, the sweating abnormalities, the GI dysmotility are outputs. The system generating those outputs is central. Treating the outputs without identifying and addressing the central driver explains why patients cycle through medication after medication without resolution — each one suppresses a peripheral manifestation of a central problem that none of them are reaching.

The Hierarchy of Autonomic Control

Standard clinical management of dysautonomia targets what is visible on testing and reachable with available medications. Tachycardia: beta-blocker or ivabradine. Low blood pressure on standing: fludrocortisone or midodrine. Each intervention addresses a peripheral effector — the heart, the peripheral vasculature — without asking what is directing that effector to behave abnormally.

Novak's argument is that this approach is mechanistically backward for a significant proportion of patients. The autonomic nervous system is hierarchically organized. The hypothalamus, brainstem nuclei — the nucleus tractus solitarius, the rostral ventrolateral medulla, the dorsal motor nucleus of the vagus — and the higher cortical inputs to these structures determine the sympathovagal balance, baroreflex set point, thresholds for vasovagal responses, and the tonic level of sympathetic outflow. The peripheral organs do what the central program tells them. If the central program is dysregulated, the peripheral symptoms are correct responses to incorrect commands. Correcting the peripheral response does not fix the command.

The clinical implication is that complete management requires identifying where in the central-to-peripheral hierarchy the primary dysfunction sits. Peripheral vasoconstriction failure, ganglionic dysfunction, spinal autonomic impairment, and central autonomic network dysregulation all produce overlapping peripheral symptoms but require different interventions. Treating them all with peripheral agents is not systematic — it is pattern-matching symptoms to available drugs without asking which level of the system is generating those symptoms.

Central Sensitization in Autonomic Dysfunction

Novak introduces the concept of central sensitization as applied to autonomic function — a mechanism more familiar in pain medicine but directly applicable to the autonomic context. Central sensitization refers to a state where the central nervous system's processing of incoming signals has been recalibrated toward higher gain: normal inputs produce abnormal outputs. In pain medicine, this produces allodynia — pain from stimuli that should not cause pain. In autonomic medicine, it produces autonomic responses to stimuli that should not trigger significant activation.

For dysautonomia patients, the manifestation is familiar: symptoms that appear disproportionate to the apparent trigger, reactivity to minor positional changes that would not produce significant responses in unaffected individuals, symptom spread across multiple systems that are all receiving commands from the same sensitized central network. The peripheral measurements capture the output of this sensitization — elevated heart rate, blood pressure variability, abnormal sweating responses — but the source is the central autonomic gain, not the peripheral effectors themselves.

Peripheral medications work at the effector end of this chain. They reduce the peripheral output of a central process they cannot reach. For patients with primarily peripheral pathology — pooling from inadequate vasoconstriction, volume deficits from RAAS dysfunction — peripheral treatment may be largely sufficient. For patients with central sensitization as a primary driver, peripheral treatment provides incomplete relief because it is addressing the wrong level of the system.

What Central Evaluation Should Include

Novak's clinical research has emphasized quantitative autonomic testing that goes beyond the standard tilt table and QSART protocol. Heart rate variability spectral analysis provides information about sympathovagal balance and baroreflex function. Quantitative sudomotor axon reflex testing maps the peripheral postganglionic sweat response. Transcranial Doppler measurement of cerebral blood flow velocity during orthostatic challenge identifies whether cerebral perfusion is falling and whether the fall precedes or follows the tachycardia.

That sequence — whether brain blood flow drops before heart rate rises — is diagnostically significant. When it does, the tachycardia is the response to the central perfusion deficit: a downstream consequence of inadequate cerebral blood flow triggering sympathetic activation. When it doesn't, the tachycardia may be primary or from a different mechanism. The sequence matters because it identifies the target. Treating a tachycardia that is compensating for cerebral hypoperfusion by suppressing the heart rate may worsen the underlying perfusion problem.

Why Peripheral Treatment Produces Incomplete Results

Novak describes a pattern familiar to many patients: beta-blockers slow the heart rate but the patient still cannot stand without cognitive symptoms and fatigue. The rate is controlled. The brain is still underperfused, because the cardiac output reduction from rate control has reduced perfusion without addressing the cerebrovascular autoregulation failure that was driving the original hypoperfusion. The symptom metric improved; the underlying hemodynamic problem worsened.

Fludrocortisone expands volume somewhat, but symptoms remain highly reactive to minor stressors because the central sensitization amplifying responses to those stressors is unchanged. Compression garments reduce venous pooling and provide modest improvement, but the central autonomic dysregulation that determines how the brain interprets and responds to that pooling continues. Each intervention provides partial, peripheral improvement. None of them reach the central driver. The patient experiences some benefit, insufficient to restore function, and the combination is judged as partially effective.

Rehabilitation and Central Recalibration

Novak's framework also changes how exercise rehabilitation is understood. Exercise training for POTS works through multiple mechanisms: plasma volume expansion, cardiac remodeling, and baroreflex recalibration. The central gain recalibration may be equally important: the brainstem nuclei that set the sympathovagal balance respond to repeated appropriate activation by resetting toward lower baseline sympathetic tone and higher parasympathetic tone. This is not a peripheral effect. It is central remodeling through use.

Pharmaceutical peripheral management cannot replicate this effect. Rate control does not recalibrate the central autonomic set point. Volume loading does not normalize central gain. The durable benefit of exercise rehabilitation in dysautonomia may come as much from the central remodeling component as from the peripheral volume expansion, explaining why exercise effects on symptoms often exceed what the peripheral hemodynamic improvements alone would predict.

What the Standard Algorithm Misses

The standard dysautonomia management algorithm — diagnose the syndrome, add a first-line agent, titrate, assess symptoms, add a second agent — is a peripheral management protocol. It does not include a step for localizing where in the central-to-peripheral autonomic hierarchy the primary dysfunction sits. It applies peripheral agents uniformly across patients with mechanistically heterogeneous conditions and produces heterogeneous, often incomplete results.

Novak's contribution is identifying why incomplete results are the predictable outcome: peripheral management applied to a problem that is partly or primarily central cannot reach what is driving the symptoms. The tachycardia is real. The blood pressure dysregulation is real. But they are outputs of a command system. What you now understand is that measuring and addressing what is upstream of the peripheral symptoms — at the level of the central autonomic network — is what separates symptom management from addressing the condition that is generating those symptoms.